SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is attracting strong investor attention as shares approach record highs, driven by a strategic $10.9 billion acquisition of Apogee Therapeutics that strengthens its immunology pipeline. Investors are also rotating into the healthcare sector for defensive stability, with the community actively discussing the company's robust drug development pipeline and sustained market momentum.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders react to anticipation surrounding the upcoming Goliath mainnet launch. While some investors are accumulating in hopes of institutional adoption, others remain skeptical, citing historical price volatility and recurring cycles of skepticism within the community.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is drawing significant attention as community members debate its potential for a rebound, with some participants linking its market performance to its relationship with other meme tokens like Updog. While some traders view the current volatility as a buying opportunity, others remain skeptical about the asset's long-term sustainability.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is trending as investors debate whether its massive $22B contracted backlog and dominant position in AI-driven warehouse automation justify its premium valuation following recent volatility. While the community remains divided over the company's concentration risk with Walmart and recent insider selling, many are actively scaling into the stock as a long-term play on the structural shift toward physical AI.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is seeing significant volatility as it faces its first-ever withdrawal caps on a major private credit fund due to record redemption requests, triggering broader investor anxiety about liquidity in the alternative asset sector. The move has prompted community debate regarding systemic risks within private credit and has put renewed downward pressure on the stock.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as investors debate the impact of its new supply cap and shifting tokenomics, with the community polarized between those accumulating at current price levels and others concerned by its significant decline from previous peaks. Sentiment remains split between long-term holders focusing on ecosystem developments and network upgrades and critics pointing to weak adoption metrics and sustained downward price action.

Themes ETF Trust - Leverage Shares 2X Long BBAI Daily ETF

Leverage Shares 2X Long BBAI Daily ETF

Investors are actively debating the merits of holding the 2X leveraged BAIG ETF versus the underlying BigBear.ai stock, with many community members focusing on volatility decay and the potential for magnified gains during market swings. The discussion is heavily polarized by varying strategies, ranging from long-term accumulation to aggressive short-term trading and speculation around future catalysts.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the company expands its oncology and immunology portfolio through strategic acquisitions and positive clinical trial readouts for its HIV treatment pipeline. The community is actively discussing the potential for long-term growth driven by these pipeline advancements and strong cash flow, alongside significant institutional interest in the company's valuation as it continues to diversify beyond its core antiviral business.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

The iShares Bitcoin ETF (IBIT) is experiencing significant downward pressure as investors rotate capital toward high-growth AI and energy stocks, while community sentiment remains divided between those panic-selling and dip-buyers labeling the price action as a major accumulation zone. Despite the negative flow and recent outflow records, bullish participants are looking past short-term volatility, citing long-term institutional adoption and the potential for a cycle-bottoming recovery later this year.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh potential M&A speculation against a long-awaited court ruling on Medicare reimbursement for XPHOZAH. While management focuses on long-term IBSRELA growth and profitability, the community remains divided between those frustrated by share price stagnation and those accumulating shares, betting that current valuations overlook future growth and potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NIO Amid reports that Volkswagen is considering up to 100,000 job cuts and four plant closures due to intense competitive pressures, rumors suggest major Chinese automakers are in preliminary talks to acquire these vulnerable manufacturing assets. Such a move would allow Chinese firms to establish a direct manufacturing footprint in Europe, bypassing escalating tariffs on imported vehicles.  
 
https://www.reuters.com/business/autos-transportation/volkswagen-ceo-aims-cut-up-100000-jobs-next-years-manager-magazin-reports-2026-06-26/

David Troupin

DavidB420

In absolute terms, laying off 100,000 people and ​axing four assembly plants would be the largest restructuring in automotive industry history.

Reuters

VW weighs up to 100,000 job cuts, four plant closures in biggest overhaul yet, sources say

StockTwits Web

NIO Inc

 Amid reports that Volkswagen is considering up to 100,000 job cuts and four plant closures due to intense competitive pressures, rumors suggest major Chinese automakers are in preliminary talks to acquire these vulnerable manufacturing assets. Such a move would allow Chinese firms to establish a direct manufacturing footprint in Europe, bypassing escalating tariffs on imported vehicles.  
 
